Table 2.
Parameters | No. of cases | Percentage (%) | α7nAChR expression Low High |
P values | |
---|---|---|---|---|---|
Total | 91 | 100 | 49 (53.8%) | 42 (46.2%) | |
Gender Male Female |
51 40 |
56.0 44.0 |
30 (33.0%) 19 (20.9%) |
21 (23.1%) 21 (23.1%) |
0.194 |
Age <65 >65 |
41 50 |
45.1 54.9 |
24 (26.4%) 25 (27.5%) |
17 (18.7%) 25 (27.5%) |
0.274 |
Stage I + II III + IV |
14 33 |
15.4 36.3 |
30 (33.0%) 19 (20.9%) |
19 (20.9%) 23 (25.3%) |
0.094 |
Parameters | No. of cases | Percentage (%) |
M3R expression Low High |
P values | |
Total | 91 | 100 | 58 (63.7%) | 33 (36.3%) | |
Gender Male Female |
51 40 |
56.0 44.0 |
31 (34.1%) 27 (29.7%) |
20 (22.0%) 13 (14.3%) |
0.508 |
Age <65 >65 |
41 50 |
45.1 54.9 |
22 (24.2%) 36 (39.6%) |
19 (20.9%) 14 (15.4%) |
0.070 |
Stage I + II III + IV |
49 42 |
53.8 46.2 |
38 (41.8%) 11 (12.1%) |
11 (12.1%) 31 (34.1%) |
0.017 |
Parameters | No. of cases | Percentage (%) |
ChAT expression Low High |
P values | |
Total | 91 | 100 | 32 (35.2%) | 59 (64.8%) | |
Gender Male Female |
51 40 |
56.0 44.0 |
30 (33.0%) 19 (20.9%) |
21 (23.1%) 21 (23.1%) |
0.194 |
Age <65 >65 |
41 50 |
45.1 54.9 |
24 (26.4%) 25 (27.5%) |
17 (18.7%) 25 (27.5%) |
0.274 |
Stage I + II III + IV |
49 42 |
53.8 46.0 |
30 (33.0%) 14 (15.4%) |
19 (20.9%) 28 (30.6%) |
0.049 |
P values are based on the frequency of cholinergic markers within each parameter